Table 2.
Global symptom scores by follow-up time
| Time | Group A | Group B | P value1 |
| Week 0 | 5.85 (5.09-6.61) | 6.10 (5.34-6.86) | 0.642 |
| Week 1 | 4.90 (4.14-5.66) | 5.10 (4.34-5.86) | 0.709 |
| Week 2 | 3.94 (3.08-4.80) | 3.90 (3.06-4.74) | 0.948 |
| Week 3 | 3.76 (2.86-4.66) | 3.95 (3.10-4.80) | 0.755 |
| Week 4 | 3.82 (2.96-4.68) | 3.90 (3.10-4.70) | 0.889 |
| Week 5 | 3.18 (2.38-3.98) | 3.80 (3.05-4.55) | 0.259 |
| Week 6 | 3.00 (2.21-3.79) | 3.95 (3.21-4.69) | 0.084 |
| Week 7 | 2.89 (2.12-3.65) | 4.05 (3.33-4.77) | 0.031 |
| Week 8 | 2.47 (1.68-3.27) | 4.37 (3.63-5.11) | 0.001 |
Data are least square means (95%CI). Group A: rabeprazole + amitriptyline group vs Group B: double dose of proton pump inhibitor group.
1
P value < 0.006 is considered statistically significant after adjusting the significance level of 0.05 using Bonferroni correction method for multiple comparisons. The significant difference between two groups was found at week 8 only (P < 0.006).